Latest Conference Articles

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Erika P. Hamilton, MD, discusses the mechanism of action of OP-1250 in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Nadia Harbeck, MD, PhD, discusses Ki-67 as a biomarker for identifying patients with high-risk early breast cancer who received treatment on the monarchE trial.

Sara M. Tolaney, MD, MPH, discusses the safety profile of SAR439859 in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Debu Tripathy, MD, discusses updated results of the phase 3 MONALEESA-7 trial in hormone receptor–positive, HER2-negative breast cancer.

Ian Kunkler, FRCP, FRCR, DMRT, MRCP, discusses the 10-year results of the PRIME 2 trial in patients with breast cancer

Kevin Kalinsky, MD, MS, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor–positive, HER2-negative breast cancer.

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

Christian Buske, MD, discusses ​the results of the iNNOVATE trial in Waldenström macroglobulinemia.

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.

Francesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.

Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.